Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...
Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...
Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax réduit sa perte trimestrielle en augmentant ses dépenses pour les vaccins COVID
La perte du quatrième trimestre de Novavax s'est réduite jeudi, grâce à la réduction des frais de vente et d'administration ...
Iowa bill asks vaccine manufacturers to waive indemnity against injury lawsuits
The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...
Novavax sees royalties, reduced expenses on COVID vaccines from Sanofi partnership
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
AOL5d
Novavax reports large quarterly revenue declines, rethinks its strategic direction
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a vaccine maker. The COVID-19 vaccine company, based in Maryland ...
Benzinga.com5d
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate. Also Read: Wegovy Maker Novo Nordisk To Buy Novavax ...
NOVAVAX, INC. : BTIG à l'achat
Novavax, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 décembre 2024 27/02 CI Novavax, Inc. annonce ses ...
Novavax, Inc.: Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's net loss was $81 million for the quarter ended December 31, compared with a net loss of $178.3 million a year ago.